MS-275 Sensitizes TRAIL-Resistant Breast Cancer Cells, Inhibits Angiogenesis and Metastasis, and Reverses Epithelial-Mesenchymal Transition in Vivo
Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-10-0582
Full Text
Open PDFAbstract
Available in full text
Date
November 1, 2010
Authors
Publisher
American Association for Cancer Research (AACR)